Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT07174349

Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

Conditions: Urinary Retention Postoperative

Sex: All
Ages: 35 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 20
Sponsor: Mayo Clinic

Location: Mayo Clinic in Rochester Rochester Minnesota

Summary

The purpose of this research is to see if the use of tamsulosin can decrease both the incidence and duration of urinary retention, as well as hospital length of stay following spine surgery.

Eligibility Criteria

Inclusion Criteria: * Cervical Laminectomy * Cervical Posterior Fusion * Cervical Anterior/Posterior Fusion * Lumbar Laminectomy * Lumbar Posterolateral Fusion * Lumbar Interbody Fusion Exclusion Criteria: * Cervical Anterior Discectomy and Fusion * Cervical Anterior Corpectomy * Cervical Posterior Discectomy * Cervical Foraminotomy * Lumbar Discectomy (METRx or Open) * Lumbar Foraminotomy * Lumbar Anterior Fusion * Myelopathy with bladder dysfunction * Patients currently taking an alpha-antagonist o The following drugs are alpha antagonists: alfuzosin, doxazosin, prazosin, terazosin, tamsulosin, and phenoxybenzamine. * Patients with history of allergy or sensitivity to tamsulosin or other alpha-antagonist * History of prostatectomy or urologic surgery involving the bladder or urethra * Severe liver disease or end-stage renal disease * Patients taking strong inhibitors of CYP3A4 o The following drugs are strong inhibitors of CYP3A4: ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir/ritonavir, lopinavir/ritonavir, and conivaptan. * Mental disability or prisoner * Pregnancy (for anesthesia purposes)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07174349). StuddyBuddy aggregates publicly available trial information.